文献速递淋巴瘤造血干细胞移植与细胞治疗

自体干细胞移植后罗米地辛维持治疗外周T细胞淋巴瘤

Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma.
PubMed 文献 · Blood Adv · 2025-01-01

这项多中心研究评估外周T细胞淋巴瘤患者在接受自体造血干细胞移植(AHCT)后使用罗米地辛维持治疗的无进展生存期(PFS)。26例在首次完全缓解(CR1)或首次部分缓解(PR1)时移植的患者纳入主要终点分析,估计2年PFS为62%(95%CI 45-83)。研究未达到预设主要疗效终点,但罗米地辛维持治疗可行。

要点

  • 26例CR1/PR1期接受AHCT的患者中,估计2年PFS为62%(95%CI 45-83)。
  • 罗米地辛14 mg/m2自AHCT后42-80天开始,按时间调整给药间隔至2年。
  • 常见毒性为乏力(n=24,73%)、血小板减少(n=16,48%)和贫血(n=16,48%)。

核心结论

  • 研究未达到预设主要疗效终点,但罗米地辛维持治疗可行,估计2年PFS为62%。

研究设计与样本

  • 多中心研究,26例CR1或PR1期接受AHCT的患者纳入主要终点分析,探索性队列包括CR/PR2期移植(n=5)或高危组织学(n=2)患者。
  • 47例患者知情同意,其中13例未接受罗米地辛。
  • AHCT采用卡莫司汀、依托泊苷、阿糖胞苷和美法仑预处理。
  • 罗米地辛14 mg/m2自AHCT后42-80天开始,AHCT后6个月内每2周一次,6个月至1年每3周一次,1至2年每4周一次。
  • 该试验在www.ClinicalTrials.gov注册,注册号为#NCT01908777。

主要发现

  • 中位无进展随访32个月(范围24-36),队列1前25例患者中15例在2年后无进展。
  • 估计2年PFS为62%(95%CI 45-83)。
  • 最常见毒性为乏力(n=24,73%)、血小板减少(n=16,48%)和贫血(n=16,48%)。

局限性

  • 研究未达到预设主要疗效终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with peripheral T-cell lymphoma (PTCL) have suboptimal outcomes. Autologous hematopoietic stem-cell transplantation (AHCT) is a therapeutic strategy for patients in first complete remission (CR1) or first partial remission (PR1), with median intent-to-treat progression-free survival (PFS) of 36% to 48%. Romidepsin is a histone deacetylase inhibitor used for treatment of relapsed/refractory PTCL. We present a multicenter study to evaluate the PFS of patients receiving maintenance therapy with romidepsin after AHCT. Twenty-six patients who underwent AHCT in CR1 or PR1 were evaluated for the primary end point of 2-year PFS. The exploratory cohort enrolled patients who underwent transplantation during or after CR/PR2 (n = 5) or high-risk histologies (n = 2). Patients underwent AHCT with carmustine, etoposide, cytarabine, and melphalan conditioning. Romidepsin 14 mg/m2 was started on days 42 to 80 after -AHCT every other week until 6 months of -AHCT, every 3 weeks between 6 months and 1-year of -AHCT, and every 4 weeks between 1 and 2 years of -AHCT. PFS was estimated using the Kaplan-Meier analysis. Forty-seven patients consented and 13 did not receive romidepsin. With a median progression-free follow-up of 32 months (range, 24-36), 15 of the first 25 patients in cohort 1 were progression-free after 2 years. The estimated 2-year PFS was 62% (95% confidence interval, 45-83). The most common toxicities were fatigue (n = 24, 73%), decreased platelets (n = 16, 48%), and anemia (n = 16, 48%). Although the study did not meet its desired primary efficacy end point, maintenance romidepsin was feasible, with a favorable estimated 2-year PFS of 62%. This trial was registered at www.ClinicalTrials.gov as #NCT01908777.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Khan N, Dahi PB, Khimani F, et al. Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma. Blood Adv. 2025. PMID: 40179392. doi:10.1182/bloodadvances.2024014263

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。